Zishuo Ian Hu

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota”.

Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota

Proceedings of the National Academy of Sciences(2022)10.1073/pnas.2200348119

N/A

0DataRank · unranked

57 citations

Verena M. Link, Djalma S. Lima‐Junior, Jérémie Delaleu, Nicolas Bouladoux, Seong‐Ji Han +3 more

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps265

N/A

0DataRank · unranked

8 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zishuo Ian Hu +6 more

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Cancer Biomarkers(2024)10.3233/cbm-230431

N/A

0DataRank · unranked

12 citations

Sunyoung S. Lee, Tarık Demir, Shadi Chamseddine, Zishuo Ian Hu, Lianchun Xiao +17 more

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma

Journal of Immunotherapy and Precision Oncology(2024)10.36401/jipo-24-6

N/A

0DataRank · unranked

8 citations

Betül Gök Yavuz, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Zishuo Ian Hu +13 more